News in Brief

AudioCure appoints Dr. Reimar Schlingensiepen as CEO

Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Rommelspacher will continue as CSO. AudioCure recently secured funding of about 9 million euros in a Series A financing round from Austrian MED-EL Elektromedizinische Geräte...

Relaunch of the AudioCure Website

It is with great pleasure that we announce the relaunch of our corporate brand and website. The brand design has been refined and updated to reflect AudioCure’s innovative and forward-thinking outlook. Meanwhile, we hope that with its clear structure, easy navigation...

AudioCure completes financing round with MED-EL and HTGF

AudioCure Pharma GmbH secures funding of about EUR 9 Million for the further development of their lead candidate, AC102, in hearing loss. Austrian company MED-EL Elektromedizinische Geräte GmbH (MED-EL), Innsbruck, the technology leader in implantable hearing...

AudioCure Pharma cooperates with Charité Universitätsmedizin, Berlin

We are very pleased to announce the start of our collaboration with Dr. Julian Hellmann-Regen, Head of the Clinical Neurobiology Laboratory at the Charité Universitätsmedizin, Berlin. Dr. Hellmann and his team will further investigate the molecular mode of action of...

Dr. Reimar Schlingensiepen has joined AudioCure

We are happy to announce that Dr. Reimar Schlingensiepen has joined AudioCure as COO. Dr. Schlingensiepen is an experienced entrepreneur and manager for biotech, medtech and diagnostics companies. He offers his leadership expertise in the multiple fields of the...

Promising in vitro results for new drug candidate

AudioCure, in collaboration with Dr. Wernicke (Technical University of Applied Sciences, Wildau), and Dr. Enzensperger (University of Jena) has successfully tested the newly synthesized chemical entity AC102, a betacarboline, in an in vitro screening model. AC102 has...

AudioCure Pharma meets Federal Minister Dr. P. Rösler

AudioCure, met with federal minister and party head Dr. Philipp Rösler, on the occasion of a biotechnology function in Berlin. We were very pleased to be invited by the German Bundestag who aimed to bring an international group of investors together with highly...